US And Canada

Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

After a two-year stint with Allied Minds, Simon Davidson has moved back to In-Q-Tel as a managing partner.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Notion Capital Venture Capital IV has added Texas A&M University to its limited partners as it seeks a $150m final close.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.